Cargando…
Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary
Autologous stem cell transplantation (ASCT) is the standard treatment of primary refractory or relapsed Hodgkin-lymphoma, which can provide a cure rate of about 50%. The aim of our study was to analyze the data of 126 HL patients undergoing AHSCT in Hungary between 01/01/2016 and 31/12/2020. We asse...
Autores principales: | Husi, Kata, Szabó, Roxána, Pinczés, László Imre, Földeák, Dóra, Dudley, Réka, Szomor, Árpád, Koller, Beáta, Gopcsa, László, Illés, Árpád, Miltényi, Zsófia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444678/ https://www.ncbi.nlm.nih.gov/pubmed/37428200 http://dx.doi.org/10.1007/s00277-023-05354-8 |
Ejemplares similares
-
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma
por: Pinczés, László Imre, et al.
Publicado: (2020) -
Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma– Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma
por: Simon, Zsófia, et al.
Publicado: (2021) -
Changing Patterns in the Clinical Pathological Features of Hodgkin Lymphoma: A Report from Debrecen, Hungary
por: Miltényi, Zsófia, et al.
Publicado: (2011) -
Pulmonary Toxicity of Hodgkin Lymphoma Treatment: A Prospective Single-Center Study
por: Jona, Adam, et al.
Publicado: (2021) -
Employment status and health related quality of life among Hodgkin-lymphoma survivors’– results based on data from a major treatment center in Hungary
por: Magyari, Ferenc, et al.
Publicado: (2017)